The development and in-vivo behavior of tin containing radiopharmaceuticals—II. Autoradiographic and scintigraphic studies in normal animals and in animal models of bone disease
Z.H. Oster(Brookhaven National Laboratory), T.A. Butler(Oak Ridge National Laboratory), P. Richards(University of Auckland), Harold Atkins(University of Ottawa), D.F. Sacker(Brookhaven National Laboratory), G.E. Meinken(Brookhaven National Laboratory), S.C. Srivastava(Chhatrapati Shahu Ji Maharaj University), F. F. Knapp(Oak Ridge National Laboratory), P. Som(Brookhaven National Laboratory), A.B. Brill(Argonne National Laboratory), Ralph G. Fairchild, D.Y. Tillman(State University of New York)
Cited by 38
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
|Journal of Computer Assisted Tomography|1980|503
Glucose Metabolic Rate Kinetic Model Parameter Determination in Humans: The Lumped Constants and Rate Constants for [ <sup>18</sup> F]Fluorodeoxyglucose and [ <sup>11</sup> C]Deoxyglucose
|Journal of Cerebral Blood Flow & Metabolism|1985|419
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
|Nuclear Medicine and Molecular Imaging|2015|375